期刊文献+

新型甲型H1N1流感危重症存活和死亡病例的临床特点分析 被引量:13

The analysis of the clinical features between survivors and non-survivors with the severe form of new influenza A ( H1N1 ) viral infection
原文传递
导出
摘要 目的 了解新型甲型H1N1流感(简称甲型流感)危重病例的临床特点,探讨与死亡相关的危险因素. 方法 采用前瞻性研究方法分析北京地坛医院2009年10月3日至12月15日收治的55例甲型流感危重病例的临床特点,并对存活病例和死亡病例进行比较分析. 结果 55例中男31例,女24例,年龄10个月至84岁,平均(38±20)岁.危重患者中〈65岁48例(48/55),肥胖33例(33/49),伴基础疾病26例(26/49),妊娠6例(6/24),临床表现为高热、咳嗽、咳痰(部分为血痰)及呼吸困难,双肺可闻及干湿性啰音.55例中54例并发呼吸衰竭,26例并发ARDS,38例需行机械通气;27例继发感染,其中肺部感染24例(呼吸机相关肺炎10例).发病早期C反应蛋白升高,平均为(131±130)mg/L,CD4+及CD8+T细胞计数降低,分别为(217±139)/μl和(162±82)/μl;随病程进展,死亡病例的C反应蛋白持续升高,T细胞亚群计数持续降低,继发真菌感染的比例明显高于存活组(P〈0.05);Logistic回归分析结果显示,体重指数高及继发真菌感染的患者病死率明显增高(OR值分别为6.512和19.631,P均〈0.05);发病48 h内使用奥司他韦抗病毒治疗者中未出现死亡病例. 结论 青壮年、肥胖、伴基础疾病和妊娠的甲型流感患者易进展为危重症;C反应蛋白水平持续升高及T细胞亚群计数持续降低提示预后不良;体重指数高及继发真菌感染者病死率高;早期应用奥司他韦治疗可降低病死率. Objective To understand the clinical features of critically ill patients with pandemic 2009 influenza A(H1N1)and investigate the risk factors associated with death cases. Methods The clinical features of 55 critically ill patients with pandemic 2009 influenza A(H1N1)viral infection hospitalized at Beijing Ditan Hospital from October 3 to December 15,2009 were retrospectively analyzed,and a comparative analysis was performed on the manifestations of the survival and the death groups of patients. Results There were 31 males and 24 females.The age ranged from 10 months to 84 year old,and the mean(SD)was 38(20)year old.The critically ill cases were more in patients under age 65(48/55),with obesity(33/49),with underlying diseases(26/49),and pregnancy(6/24).Both the survivors and non-survivors of patients had high fever,cough,sputum(some sputum with blood),dyspnea,r(a)les of both lungs fields.and all further developed severe pneumonia.The patients also showed respiratory failure(54/55)and ARDS(26/55).All of them received oseltamivir therapy,and 38 patients received mechanical ventilation and 30 were giyen steroid therapy.Secondary infection occurred in 27 cases.and ventilatorassociated pneumonia happened in 10 patients.In the early stage of onset,C-reactive protein(CRP) increased [ (131 ± 130)mg/L] and low counts of T lymphecytes were present [ CD4+ , CD8+T was (217 ±139)/μl and (162 ± 82)/μl]. With the progress of disease, the non-survival cases had persistently increased CRP and the counts of T lymphocytes did not recover, while the secondary fungal infection was significantly higher than in the survivor cases (P 〈0. 05). By using BMI, underlying diseases, ARDS, the day of Oseltamivir initiated, steroid therapy, following bacterial and fungal infection as variables through logistic regression analysis, it was shown that higher BMI and following fungal infection were associated with higher fatal risks ( OR was 6. 512, 19. 631 respective0ly, both of P value was low than 0. 05 ). There was no death case who received oseltamivir treatment within 48 hours of onset of disease. Conclusions Critical illness in pandemic 2009 influenza A (H1N1)was associated with patients under age 65, with obesity,underlying diseases, and pregnancy. Persistently increased CRP and lower counts of T lymphocytes were associated with unfavorable prognosis. The patients with higher BMI and secondary fungal infection had higher fatal risks. Oseltamivir treatments at early stage would probably reduce mortality.
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2010年第6期406-410,共5页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 国家科技部支撑计划课题基金甲型H1N1流感联防联控应急科研项目基金资助项目(2009ZX10004-016)
关键词 流感病毒A型 H1N1亚型 危重病 C反应蛋白 抗病毒药 Influenza A virus, H1N1 subtype Critical illness C-reactive protein Antiviral agents
  • 相关文献

参考文献12

  • 1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3060
  • 2ANZIC Influenza Investigators,Webb SA,Pettil(a) V,et al Critical care services and 2009 H1N1 influenza in Australia and New Zealand.N Engl J Med,2009,361:1925-1934.
  • 3Jain S,Kamimoto L,Bramley AM,et al.Hospitalized patients with 2009 H1N1 influenza in the United States,April-June 2009.N Engl J Med,2009,361:1935-1944.
  • 4Echevaría-Zuno S,Mejía-Aranguré JM,Mar-Obeso AJ,et al.Infection and death from influenza A H1N1 virus in Mexico:a retrospective analysis.Lancet,2009,374(9707):2072-2079.
  • 5Louie JK,Acosta M,Winter K,et al.Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California JAMA,2009,302:1896-1902.
  • 6World Health Organization.Clinical management of human infection with pandemic (H1N1) 2009:revised guidance[EB/OL].[2009-11-30].Http://www.Who.Int/csr/resources/publications/swineflu/clinical_management/en/index.Html.
  • 7Domínguez-Cherit G,Lapinsky SE,Macias AE,et al.Critically Ⅲ patients with 2009 influenza A(H1N1)in Mexico.JAMA,2009,302:1880-1887.
  • 8Smith JR,Ariano RE,Toovey S.The use of antiviral agents for the management of severe influenza.Crit Care Med,2010,38 (4 Suppl):e43-e51.
  • 9Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators,Davies A,Jones D,et al.Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome.JAMA,2009,302:1888-1895.
  • 10景海涛.呼吸机相关性肺炎[J].医学综述,2008,14(12):1847-1850. 被引量:15

二级参考文献47

共引文献3098

同被引文献69

引证文献13

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部